Holocene Advisors
AXSM icon

Holocene Advisors’s Axsome Therapeutics AXSM Stock Holding History

Holocene Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-529,144
Closed -$32.6M – 719
2023
Q1 		$32.6M Buy
+529,144
New +$34.8M 0.16% 165

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors's AXSM Position: Q2 2023 in Review

Holocene Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2023, closing a stake of 529,144 shares — an estimated $32.6M sold.

Holocene Advisors first reported a position in AXSM in Q1 2023 and held it in 1 quarter. The position peaked at $32.6M in Q1 2023. 231 funds tracked by Wall St. Rank hold AXSM as of Q2 2023.

  • Holocene Advisors reported no remaining Axsome Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Holocene Advisors sold 529,144 Axsome Therapeutics shares in Q2 2023, an estimated $32.6M.
  • Holocene Advisors first reported a position in Axsome Therapeutics in Q1 2023 and held it in 1 quarter.
  • Holocene Advisors's Axsome Therapeutics position peaked at $32.6M in Q1 2023.
  • 231 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2023.

Based on Holocene Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.